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study, we examined thermal hyperalgesia provoked by peripheral injection of complete
Freund's adjuvant (CFA) to test for Cdk5 signaling in the spinal dorsal horns of rats through
the p38 mitogen-activated protein kinase (p38 MAPK) signaling pathway, which is known
to function in mediating inﬂammatory pain.
Methods: We induced the inﬂammatory pain model by plantar injection of CFA and
compared the inhibitory effects of roscovitine and SB203580 on thermal hyperalgesia. We
measured localization of Cdk5, p35, OX-42, and glial ﬁbrillary acidic protein (GFAP) in the
dorsal horn at 1 and 3 days after CFA injection using immunohistochemistry, and we
measured protein levels of OX-42 and phosphorylated-p38 (p–p38) using Western blot
analysis. Tumor necrosis factor-a (TNF-a) was measured by ELISA.
Results: The maximum thermal hyperalgesia induced by CFA occurred at 1d following
injection and decreased until 5 d. We found colocalization of the Cdk5 activator p35, the
microglial marker OX-42 and p–p38 in the same microglial cells and neurons of the spinal
cord at day 1 after CFA injection; however, we saw no colocalization of p35 and GFAP, a
marker of activated astrocytes. The thermal hyperalgesia induced by CFA was inhibited by
intrathecal administration of the Cdk5 inhibitor roscovitine and by the p38 inhibitor SB203580.
Furthermore, the expression of OX-42, p–p38, and TNF-a was remarkably increased from days
1 to 5 post-CFA injection and were signiﬁcantly reversed by roscovitine between 1 and 3 days.6
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b r a i n r e s e a r c h 1 6 1 9 ( 2 0 1 5 ) 1 6 6 – 1 7 5 167Conclusions: Cdk5, an upstream regulator of p38 and TNF-a, mediates CFA-induced thermal
hyperalgesia. As such, pharmacological blocking of the generation of p–p38 mediated by Cdk5
may present a novel approach for diminishing inﬂammatory pain.
This article is part of a Special Issue entitled SI: Spinal cord injury.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Little is known the anti-nociceptive role of cyclin-dependent
kinase 5 (Cdk5) which previously belongs to serine/threonine
kinase. Wang et al. (2004), ﬁrstly reported that the morphine
tolerance development can be signiﬁcantly attenuated by
intrathecal administration of Cdk5 inhibitor roscovitine, which
has laid down the important foundation for further study of
Cdk5 mediating the pain hypersensitivity. Latter studies indi-
cated that Cdk5 mainly mediated thermal hyperalgesia
induced by inﬂammation (Pareek et al., 2006, 2007; Yang
et al., 2007; Utreras et al., 2011; Zhang et al., 2012a, 2012b;
Xing et al., 2012; Zhang et al., 2012a, 2012b). –In contrast to
other Cdks, regulation of Cdk5 activity is mediated by speciﬁc
activator proteins (p35 or p39) or their variants (p25 or p30)
(Zheng et al., 1998). Cdk5 in the dorsal root ganglion (DRG) of
rats is an upstream modulator of complete Freund's adjuvant
(CFA)-induced thermal hyperalgesia via its effects on mem-
brane trafﬁcking of the transient receptor potential channel
and phosphorylation of the vanilloid receptor 1 (Xing et al.,
2012; Pareek et al., 2007). And thus, the activities of Cdk5 and
p35 were signiﬁcantly increased upon peripheral injection of
CFA, whereas Cdk5 activity and associated thermal hyperalge-
sia in this model were both inhibited by Cdk5/p35 knockdown
or by intrathecal administration of roscovitine, a speciﬁc
inhibitor of Cdk5 (Yang et al., 2007). Nevertheless, the mechan-
isms underlying mediation of inﬂammation-induced thermal
hyperalgesia by Cdk5 remain poorly understood.
In addition to its function in inﬂammation pain, Cdk5 has
been implicated in the pathogenesis of Alzheimer's disease
via its action as a key upstream regulator of p38. In this
conceptual model, pharmacological inhibition of Cdk5 pre-
vented p38 activation in neurons upon stimulation with the
excitatory amino acid glutamate (Chang et al., 2010). In
particular, roscovitine signiﬁcantly inhibited the expression
of increased p–p38 protein levels in microglia following
exposure to glutamate. The mitogen-activated protein kinase
(MAPK) family includes extracellular signal-regulated kinase
(ERK), p38 MAPK, and c-Jun N-terminal kinase, and ERK and
p38 MAPK together are thought to be involved in modulating
inﬂammation-induced pain hyperalgesia in the DRG and
spinal cord (Piao et al., 2006; Boyle et al., 2006; Ji et al.,
2002); however, Yang et al. (2007) failed to examine an
obvious role for ERK1/2 in mediating the thermal hyperalge-
sia mediated by Cdk5 in the CFA-induced inﬂammatory pain
model. Based on the general ﬁndings of a linkage between
Cdk5 and activated p38 in modulating inﬂammatory pain, in
the present study, we tested the hypothesis that Cdk5
mediated pain hypersensitivity via the p38 MAPK signaling
pathway.2. Results
2.1. Activated p38 in the spinal cord was restricted
entirely to microglia and neurons following plantar injection of
CFA
In different inﬂammatory pain models, the activated p38
MAPK functions in mediating the cell signaling pathway in
glial cells and neurons. Based on the close association
between p38 MAPK and glial cells and neurons, we character-
ized their colocalization using double-immunoﬂuorescence
(Fig. 1). In our model, results of double immunoﬂuorescence
analysis demonstrated that p–p38 was not colocalized with
GFAP in astrocytes in L4 and L5 at day 1 post-CFA injection
(Fig. 1A–D). In contrast, this result indicated complete colo-
calization of p–p38 and OX-42 in microglia in dorsal horn of
the spinal cord at days 1 and 3 (Fig. 1I–P). We also observed
that p–p38 weakly colocalized with NeuN, a neuronal marker,
in neurons (in dorsal horn of the spinal cord) at day 1 post-
CFA injection (Fig. 1E–H).2.2. Activated p35 in the spinal cord was restricted
entirely to microglia and neurons in the spinal cord at L4/L5
following plantar injection of CFA
As the activator of Cdk5, p35 functions in activating Cdk5 and
mediating the signaling pathway of inﬂammatory pain. We
observed the colocalization between p35 and glial cells and
neurons using double immunoﬂuorescence. Our results
demonstrated that p35 and NeuN colocalized with Cdk5 in
neurons in dorsal horn of the spinal cord at day 1 post-CFA
injection (Fig. 2A–H); however, p35 was not colocalized with
GFAP in astrocytes in the L4 and L5 spinal cord in our model
(Fig. 2I–L). In contrast, complete colocalization of p35 and OX-
42 was observed in microglial cells in dorsal horn of the
spinal cord at days 1 and 3 post-CFA injection (Fig. 2M–T).
This ﬁnding suggests that besides the neuronal signaling
pathway, Cdk5/p35 mediated the inﬂammatory pain via the
microglia signaling pathway rather than the astrocytic
pathway.2.3. Thermal hyperalgesia induced by intraplantar CFA
injection was signiﬁcantly reversed by intrathecal
administration of either roscovitine or SB203580
It is well known that thermal hyperalgesia was closely asso-
ciated with inﬂammatory pain. In our study, we observed the
changes in nociceptive behavior following CFA peripheral injec-
tion from 1 day to 5 days by measuring thermal PWLs.
Additionally, we tested effects of both of roscovitine (a Cdk5
inhibitor) and SB203580 (a p38 inhibitor) on the thermal PWLs,
Fig. 1 – Colocalization of p–p38 with OX-42 and NeuN. Double-immunoﬂuorescence staining for p–p38 (red), GFAP (green),
Hochest [a cell nuclear marker (blue)], NeuN [an important structural protein in neurons (green)] and OX-42 (green) in
ipsilateral spinal cord L4/L5 sections 1 day [A–L] and 3 days [M–P] post-CFA injection, seperately. p–p38 was not colocalized
with GFAP in astrocytes 1 day post-CFA injection (D, white arrow head) (A–D). p–p38 was colocalized with OX-42 in microglia 1
and 3 days post-CFA injection (P, white arrow head) (I–P). p–p38 was weakly colocalized with NeuN in neurons 1 day post-CFA
injection (H, white arrow head) (E–H). (n¼3 per group, magniﬁcation X40, scale bar¼20 lm).
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day following injection of CFA into rat ipsilateral hind paws and
lasted for 5 days. The mean thermal PWL threshold (seconds) of
ipsilateral hind paws was signiﬁcantly reduced post-CFA injec-
tion from days 1 to 5 (day 1, 2.3270.63 s; day 3, 4.4270.72 s; day
5, 5.6870.82 s) compared to that in the contralateral hind paws
injected with saline in the same group during the same time
span (day 1, 10.7371.54 s (s); day 3, 11.4370.71 s; day 5,11.0370.73 s, nnpo0.01, Fig. 3A, n¼6); however, no obvious
change was observed between the ipsilateral and contralateral
hind paws of the DMSO control group challenging with saline
(p40.05, Fig. 3A, n¼6). Additionally, the decreased average
ipsilateral paw PWL thresholds were signiﬁcantly reversed by
pre-treatments with roscovitine or SB203580 30min prior to CFA
injection from days 1 to 5 (day 1, 5.2670.98 s; day 3, 6.4270.36 s;
day 5, 7.2370.32 s) and (day 1, 4.7570.74 s; day 3, 7.1270.27 s;
Fig. 2 – Colocalization of p35 with OX-42 and NeuN but not GFAP. Double-immunoﬂuorescence staining for p35 (red), Cdk5
(green), Hochest [a cell nucleus marker (blue)], NeuN [an important structural protein for neuron (green)], and GFAP (green) in
the ipsilateral spinal cord L4/L5 sections 1 day [A–M] and 3 days [Q–T] post-CFA injection, seperately. p35 was colocalized with
Cdk5 in neurons 1 day post-CFA injection (D, white arrow head) (A–D). p35 was colocalized with NeuN in neurons 1 day post-
CFA injection (H, white arrow head) (E–H). p35 was not colocalize with GFAP in astrocytes 1 day post-CFA injection (L, white
arrow head) (I–L). p35 was colocalized with OX-42 in microglia 1 and 3 days post-CFA injection (T, white arrow head) (M–T)
(n¼3 per group, magniﬁcation X40, scale bar¼20 lm).
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b r a i n r e s e a r c h 1 6 1 9 ( 2 0 1 5 ) 1 6 6 – 1 7 5170day 5, 7.4570.71 s) compared to ipsilateral paws from animals
pretreated with DMSO between 1 d and 3 d post-CFA injection
(day 1, 2.3670.70; day 3, 4.6570.83 s; day 5, 6.1670.58 s),
(nnpo0.01, Fig. 3B, n¼6).Fig. 3 – Thermal hyperalgesia induced by CFA injection was
signiﬁcantly reversed by administration of roscovitine or
SB20358. PWL to the thermal stimulus signiﬁcantly
decreased following intraplantar injection of CFA from 1 d to
5 d (**po0.01, n¼6 per group) (A). PWL to the thermal
stimulus signiﬁcantly increased following intrathecal
injection of roscovitine or SB20358 30 min prior to the CFA
injection compared to the PWL of the control group
pretreated with DMSO (**po0.01) (B). (n¼6 per group).
Fig. 4 – Ox-42 protein levels were signiﬁcantly upregulated in s
roscovitine. Compared to the control group, Ox-42 expression w
intraplantar injection of CFA. (*po0.05) (A). Increased Ox-42 pro
roscovitine compared to the DMSO-treated controls between da2.4. OX-42 upregulation in rat spinal cords following CFA
challenge was reduced by pretreatment with roscovitine
Based on the duration of thermal hyperalgesia induced by
CFA injection, in the present study, we observed the changes
in protein expression of OX-42 over time using Western blot
analysis. The ipsilateral tissues of the L4/L5 segment of the
spinal cord dorsal horn of rats were removed and used for
Western blot analysis 1 to 7 days following CFA injection.
Results showed that OX-42 was signiﬁcantly upregulated
post-intraplantar injection with CFA between days 1 and 5
(day 1, 1.3470.06; day 3, 1.4970.14; day 5, 1.3170.27) and
decreased (0.6770.19) by day 7 compared to the control group
(0.6470.01, npo0.05, Fig. 4A, n¼3). Furthermore, increased
levels of OX-42 were signiﬁcantly decreased by administra-
tion of roscovitine between days 1 and 3 (0.5970.03 at day 1,
0.3970.02 at day 3) compared to expression levels observed in
the DMSO group (1.0470.02 at day 1, 0.9370.06 at day 3,
npo0.05, Fig. 4B, n¼3).2.5. p–p38 upregulation in rat spinal cords following CFA
challenge was reduced by pretreatment with roscovitine
To examine the changes in p–p38 protein expression in our
model, the ipsilateral tissues of the L4/L5 segment from the
dorsal horn of the spinal cord were dissected. Western blot
analysis was performed from 1 to 7 days following CFA
injection. The results showed that p–p38 was signiﬁcantly
upregulated post-CFA injection from days 1 to 5 (day 1,
1.0070.03; day 3, 1.1970.05; day 5, 1.327033) and decreased
(0.6770.19) by day 7 compared to the control group
(0.6370.15, npo0.05, Fig. 5A, n¼3). Additionally, increased
levels of p–p38 induced by CFA were signiﬁcantly decreased
by administration of roscovitine between days 1 and 3
(0.5770.05 at day 1; 0.4870.00 at day 3) compared topinal cord dorsal horns, but the increase was blocked by
as signiﬁcantly increased from day 1 to day 5 following
tein levels were decreased by intrathecal injection of
ys 1 and 3 (*po0.05) (B). (n¼3 per group).
Fig. 5 – p–p38 protein levels were signiﬁcantly upregulated in spinal cord dorsal horns, but the increase was reversed by
roscovitine. Compared to the control group, p–p38 expression was signiﬁcantly increased from day 1 to day 3 post-CFA
injection (*po0.05) (A). Increased p–p38 protein levels were decreased by intrathecal injection of roscovitine compared to the
DMSO-treated controls between days 1 and 3 postCFA injection (*po0.05) (B).
Fig. 6 – TNF-α release was remarkably increased in spinal
cord dorsal horns, but the increase was reversed by
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day 1; 0.9070.13 at day 3, npo0.05, Fig. 5B, n¼3).
2.6. TNF-α upregulation in rat spinal cords following CFA
challenge was reduced by pre-treatment with roscovitine
Given that TNF-α functions in mediating inﬂammatory pain via
p–p38 (Hanisch, 2002), we examined whether Cdk5 mediated the
thermal hyperalgesia via the TNF-α pathway. The ipsilateral
tissues of the L4/L5 segment of the spinal cord dorsal horn were
removed and used for ELISA 1–7 days following CFA injection. We
found that the level of TNF-α was signiﬁcantly increased from
day 1 to 3 (day 1, 0.7870.10; day 3, 0.9870.12, day 5, 0. 0.7270.11)
and decreased (0.4170.11) by day 7 compared with the control
group (0.3370.10, npo0.05, Fig. 6A, n¼6). Furthermore, results
showed that the increased TNF-α levels were remarkably reduced
by roscovitine at days 1 and 3 following CFA injection between 1
day and 3 day (0.3870.11 at day 1; 0.4870.13 at day 3) compared
to the expression levels observed in the DMSO group (0.8770.11
at day 1; 1.0870.12 at day 3, npo0.05, Fig. 6B, n¼6).
Collectively, these data suggest that Cdk5 mediated the
thermal hyperalgesia induced by CFA injection from 1d to 5
days partly by blocking the transferring pathway between p–
p38 and TNF-α (Fig. 7).roscovitine. Compared to the control group, p-p38
expression was signiﬁcantly increased from day 1 to 5 post-
CFA injection. (*po0.05)(A). Increased TNF-α levels were
clearly decreased by intrathecal injection of roscovitine
compared to DMSO-treated controls between days 1and 3
postCFA injection (*po0.05) (B). (n¼6/group).3. Discussion
In the present study, our results showed that the maximum
thermal hyperalgesia induced by peripheral injection CFA
occurred at 1 day following injection and decreased until 5
days. In our model, immune-positive expression of p–p38
was prominently distributed in the microglia and was
colocalized with OX-42 in the dorsal horn of the spinal cord
and weakly distributed in neurons 1 day post-CFA injection.Additionally, p35 was highly colocalized with OX-42 at days
1 and 3 post-CFA injection. In contrast, colocalization of p35
and GFAP, a marker of activated astrocytes, was not
observed in the spinal cord at the same time point. The
Fig. 7 – Hypothesized pathway of Cdk5-mediated
inﬂammatory pain induced by CFA. Peripheral
inﬂammation stimulation causes the nociception in the rats,
which may increase the Cdk5/p35 activity in the spinal cord.
The elevated Cdk5 activity then increased p38 activity and
the levels of TNF-α release in microglia in the spinal cord,
ultimately, leading to pain hypersensitivity by Cdk5/p35-
p38 dependent signaling pathway in microglia.
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upstream regulator of phosphorylation of p38 and TNF-α,
mediates thermal hyperalgesia induced by peripheral injec-
tion of CFA. Unlike other Cdks, Cdk5 kinase activity is
generally thought to be associated with its activator p35,
which is mainly expressed in neurons rather than microglia
or astrocytes (Zheng et al., 1998). Our present results
showed p35 expression in neurons as well as in microglia
at days 1 and 3 post-CFA injection, suggesting that Cdk5/
p35 may mediate thermal hyperalgesia induced by periph-
eral injection of CFA between neurons and activated micro-
glial cells. Meanwhile, the experimental data indicated that
p–p38 and p35 were weakly colocalized with NeuN, and that
the thermal hyperalgesia mediated by Cdk5 in CFA-induced
inﬂammatory pain was not mainly mediated via p–p38
interacting with the neuron system. Previous studies
demonstrated that glial cells (microglia and astrocytes) in
the central nervous system function in mediating periph-
eral insults (Lee et al., 2010). As determined by upregulation
of glial cell markers, both microglia and astrocytes are
activated when a variety of peripheral nerve injuries occur,
including nerve transection, ligation, crushing, and chemi-
cal insult (Zhuang et al., 2007; Garrison et al., 1991). Results
reported by other laboratories have demonstrated that the
protein levels of OX-42 and GFAP are signiﬁcantly upregu-
lated in inﬂammatory and pathological pain models due to
the activation of both microglia and astrocytes (Lee et al.,
2010; Zhuang et al., 2007; Garrison et al., 1991; Kalla et al.,
2001; Fu et al., 1999; Svensson et al., 2003). In the present
study, p–p38 was exclusively colocalized with OX-42 in the
dorsal horn on the side that was injected with CFA. Hanisch(2002) showed that activated microglia are a source of
multiple cytokines, including interleuin-1β (IL-1β), IL-6,
and tumor necrosis factor-a (TNF-α). These cytokines are
likely to contribute to different features of pathological
pain, although their role within the spinal cord has not
been fully explored (DeLeo and Yezierski, 2001). A recent
study demonstrated that reveratrol, an inhibitor of Cdk5,
with effects similar to the compounds used in the present
study, regulated the p35 promoter activity in PC12 cells and
DRG neurons and blocked the activation of p35 induced by
TNF-α, such that subsequent Cdk5 kinase activation was
inhibited (Utreras et al., 2011), and thus, we proposed that
roscovitine might reverse the thermal hyperalgesia induced
by peripheral injection of CFA by inhibiting secretion of
TNF-α trigged by p–p38. The results of our experiments
indicated that the release of TNF-α was signiﬁcantly
increased 1 and 3 days post-CFA injection and that an
increase in TNF-α were remarkably reduced by pre-
treatment with roscovitine. These ﬁndings indicate that
the p–p38 and TNF-a signaling pathways were involved in
the inﬂammation mediated by Cdk5.
While concurring with some earlier ﬁndings, our results
showed that p35 was exclusively colocalized with OX-42 in
the spinal cord, which seemed to be at odds with the previous
studies, demonstrating that p35 was exclusively colocalized
with GFAP in the hippocampal CA1 zone (He et al., 2007). This
discrepancy between the two experiments may be due to the
different models of experimental treatments; however, the
implication is that Cdk5/p35 is indeed activated in microglia
and astrocytes but only under appropriate conditions. A
previous study demonstrated that intrathecal injection of
roscovitine markedly attenuated thermal hyperalgesia
induced by peripheral injection of CFA by inhibiting Cdk5
kinase activity (Yang et al., 2007). The present study revealed
that the inhibition of p38 by SB20358 and Cdk5 inhibition by
roscovitine signiﬁcantly reversed the lowered threshold of
thermal hyperalgesia induced by CFA from 1 d to 5 d
following CFA injection. Furthermore, p–p38 protein levels
in the dorsal horn were obviously increased between days 1
and 5 post-CFA injection, but this increase was reversed by
intrathecal injection of the Cdk5 inhibitor roscovitine, sug-
gesting that inhibition of Cdk5 kinase activity, as the
upstream regulator of p38, reduced the nociceptive behavior
by inhibiting the p–p38 signaling pathway, however, previous
studies in the CFA-induced inﬂammatory pain model showed
that roscovitine at a dose of 100 mg had no obvious effects on
expression of p-Erk1/2, a kinase belonging to the MAPK family
(Yang et al., 2007). Insofar as p38 MAPK and ERK belong to the
same family of MAPKs, the mechanism by which ERK med-
iates inﬂammatory pain in its capacity as an extracellular
signal-regulated kinase must be different from that of the
intracellular kinase p38 (Han et al., 2012). The kinase product
p–p38 serves to transduct the pain message from nuclei of
neurons and glial cells to an extracellular site. In contrast, the
ERK signaling pathway mediates pain sensitization from
extracellular sites to the nucleus of neurons and glial cells.
Considerable evidence shows that occurrence of pain
sensitization entails various factors and alterations in both
neurons and glial cells (microglia and astrocytes) rather than
arising from a single factor or single cell population
b r a i n r e s e a r c h 1 6 1 9 ( 2 0 1 5 ) 1 6 6 – 1 7 5 173(McMahon et al., 2005; Scholz and Woolf, 2007; Milligan and
Watkins, 2009). In the present study, p–p38 was weakly
colocalized in the neurons of the spinal cord, demonstrating
that p38 perhaps does not have a principle role in mediating
the CFA-induced inﬂammatory pain in neurons.
We found that experimentally induced hyperalgesia was
associated with increased protein expression of OX-42 in the
lumbar cord. Intrathecal injection of roscovitine signiﬁcantly
reduced the protein level of OX-42 at days 1 and 3 post-CFA
application to the plantar paw. The thermal hyperalgesia
development from 1 day to 5 days following CFA injection
seemed not at odds with the changing of OX-42 protein
expression. We similarly found that increased protein levels
of p–p38 and TNF-α were signiﬁcantly reversed by intrathecal
injection of roscovitine, which suggested that inhibition of
Cdk5 kinase activity by roscovitine inhibited the activation of
microglia in the CFA-induced inﬂammatory pain model.
Although the activities of Cdc2, Cdk2, and Cdk5 kinases
are all inhibited by roscovitine (Meijer et al., 1997), our
previous ﬁndings suggest that effects of roscovitine are
conﬁned mainly to Cdk5 activity rather than Cdks in adult
rats (Zhang et al., 2012a, 2012b). Consequently, we conclude
that spinal administration of roscovitine mainly inhibited
activation of microglia and the p–p38 and TNF-a signaling
pathway by inhibiting Cdk5 activity. Additionally, the sup-
pression of increased p–p38 protein expression by roscovitine
at days 1 and 3 and the persistence of attenuation of thermal
hyperalgesia in our model for over 5 days suggest that p–p38
is partly involved in the thermal hyperalgesia mediated by
Cdk5. Meanwhile, due to the fact that the overall activities of
Cdk5 and p–p38 were not inhibited by roscovitine and
SB20358 and other possible cell signaling pathways involved,
the thermal hyperalgesia by CFA injection cannot be utterly
inhibited by roscovitine and SB20358 as we expected.Future
studies are required to elucidate the mechanism of action in
the gene based model including Cdk5 and p–p38 gene knock-
out. Taken together, we hypothesize that pathway of Cdk5-
mediated inﬂammatory pain induced by CFA may be that the
nociception caused by CFA injection leads to an increase in
Cdk5/p35 activity in the spinal cord and the elevated Cdk5
activity, then increases p38 activity and the levels of TNF-a
release in microglia in spinal cord, ultimately resulting in
pain hypersensitivity by Cdk5/p35-p38 dependent signaling
pathway in microglia, which is a possible demonstration of
how the enhanced expression of OX-42, p–p38 MAPK and
TNF-a was reduced by roscovitine as well.4. Conclusion
Our study demonstrated that p35 was colocalized with OX-42
in the dorsal horn of the spinal cord in rats with CFA-induced
inﬂammation. Spinal administration of the Cdk5 inhibitors
roscovitine or SB20358 markedly alleviated the CFA-induced
thermal hyperalgesia in a behavioral assay. Increased protein
levels of OX-42, p–p38 MAPK and TNF-a in the spinal cord
were signiﬁcantly reversed by intrathecal administration of
roscovitine, suggesting that Cdk5, as the upstream regulator
of p38, functions in inducing and developing the early stage
of chronic inﬂammatory pain. The results of our studyindicate that the p38 signaling pathway contributes to
inﬂammation-induced thermal hyperalgesia mediated by
Cdk5 in rats. Consequently, we proposed that breaking down
the association between Cdk5 and the p38 signaling pathway
may present a potential therapeutic target for diminishing
inﬂammatory pain.5. Experimental procedures
5.1. Animals
One hundred twenty adult male Sprague–Dawley rats (200–
250 g) obtained from the Animal Center of Nanjing Medical
University were used in our experiments. All surgical and
experimental procedures were reviewed and approved by the
Committee of Animal Use for Research and Education of
Nanjing Medical University and were in accordance with the
guidelines established by the Committee on Ethical Issues of
the International Association for the Study of Pain (Charlton,
1995). Rats were housed at a temperature of 2272 1C under a
standard 12/12 h light/dark cycle and had free access to food
and water. The animals were allowed to acclimate to the
housing facilities for 1 week prior to beginning the experi-
ments, and all efforts were made to minimize stress and the
number of animals used.5.2. CFA administration
The ﬁrst experiment was conducted to test the effects of CFA
on thermal hyperalgesia in rats. CFA (100 ml, Sigma, St. Louis,
MO) was injected into the plantar surface of the left hind paw
of six rats and saline100 ml was injected into the right hind
paw of at the same group. As a control, saline (100 ml) was
injected into the plantar surface of the left hind paw of six
rats and the right hind paw of another six rats. Behavioral
analysis and cell testing were performed as described below.5.3. Catheter insertion and drug administration
Drugs were delivered by intrathecal injection as previously
described, but with a slight modiﬁcation (Yaksh and Rudy,
1976). In brief, rats were anesthetized with pentobarbital
(40 mg/kg i.p.) and a spinal catheter (PE-10: 0.28 mm i.d. and
0.61 mm o.d., Clay Adams, Parsippany, NJ, USA) was inserted
between lumbar vertebrae 4 and 5 (L4 and L5). Following
recovery from anesthesia and catheter insertion, veriﬁcation
of the proper placement of the catheter was conﬁrmed by
injecting 5 ml of 2% lidocaine ﬂushed with 15 ml of saline;
successful insertion of the catheter was conﬁrmed if the rat
presented with impairment of hind limb motor function for
10 s post-lidocaine administration. On the day of catheter
insertion and for 4 days thereafter, rats received daily injec-
tions of saline vehicle in 10% DMSO, 100 mg of roscovitine
(Sigma, St. Louis, MO, R7772) or 30 mg of SB203580 (Sigma
S8307) (drugs dissolved in 10% DMSO), followed by ﬂushing of
the syringe with 15 ml of sterile saline. In this experiment, the
CFA administration took place on the ﬁrst day only at 30 min
after the intrathecal injections. Each of the three treatment
b r a i n r e s e a r c h 1 6 1 9 ( 2 0 1 5 ) 1 6 6 – 1 7 5174groups included 24 rats (six each for the right and left hind
paw for the CFA and saline treatments).
5.4. Behavioral testing
Thermal hyperalgesia was quantiﬁed by measuring paw
withdrawal latencies (PWLs) to radiant thermal stimulation
as previously described (Hargreaves et al., 1988). In brief,
radiant thermal was directed to the plantar surface of each
hind paw through a 1 mm thick glass plate. To avoid over-
thermaling the skin, exposure was terminated after a max-
imum of 20 s. The time between onset of the stimulus and
the initiation of paw withdrawal was recorded as the thermal
nociceptive latency period. Prior to the behavior test, rats
were allowed to acclimate to the chamber for 30 min, and
then the thermal stimulus was delivered sequentially to the
ipsilateral and contralateral hind paws of the rats. PWLs were
measured in triplicate trials 5 min apart for each paw at day
0, 1, 3, and 5 post-CFA or saline administration. The interval
between PWL measurement of the right and left paws was
5 min. PWL measurements for rats in the CFA vs. saline test
and the DMSO, roscovitine, and SB203580 experiment were
taken in an identical manner.
5.5. Immunoﬂuorescent staining
Animals were deeply anesthetized with sodium pentobarbital
(4100 mg/kg i.p.) 1 and 3 days post-CFA injection and
perfused transcardially with 4% paraformaldehyde. For each
rat, the L4/L5 segment from the ipsilateral spinal cord dorsal
horn tissues was rapidly removed and cryoprotected over-
night in 30% sucrose at 4 1C, embedded with Tissue-Tek
(Sakura Finetek, Torrance, CA, USA), and frozen in dry ice
powder. Next, 16 mm thick transverse sections were cut in a
cryostat at 28 1C. For double immunoﬂuorescence analysis,
sections were suspended in bovine serum albumin (BSA) and
incubated with appropriate antibodies (anti-Cdk5, 1:200,
Abcam [Cambridge, MA, USA] ab115812; anti-p35, 1:200, Cell
Signaling 2680; anti-NeuN 1:100, Abcam ab104224; anti-OX-
42, 1:200, Abcam [Cambridge, MA] ab78457; anti-p-p38, 1;100
Cell Signaling; and GFAP, 1:200 Cell Signaling 3670) overnight
at 4 1C, followed by washing and incubation with the corre-
sponding secondary antibodies overnight at 4 1C. The double-
stained images were examined using an Axiovert/LSM 510
confocal scanning microscope (Carl Zeiss Microimaging, Inc.,
Germany). The experiment was repeated three times with
similar results.
5.6. Protein extraction and Western blot analysis
Tissues of spinal lumbar enlargements from unperfused
animals from the respective treatment groups were rapidly
removed and homogenized in ice-chilled lysis buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 1.5 mM MgCL2, 10% glycerol, 1%
Trition X-100, 5 mM EGTA, 0.5 mg/ml leupetin, 1 mM PMSF,
1 mM Na3VO4, 10 mM NAF, and a proteinase inhibitor cock-
tail). Homogenates were centrifuged at 12,000 g for 15 min
at 4 1C, and protein concentrations were determined using a
BCA assay kit (Pierce, Rockland, IL, USA). Portions containing
30 mg of protein were separated by SDS-PAGE and transferredonto PVDF membranes. Post blocking was obtained by incu-
bation with 1% BSA in TBST (50 mM Tris–HCl, pH 7.5, 150 mM,
NaCl, 0.05% Tween 20) for 1 h at room temperature. The
membranes were then incubated overnight at 4 1C with
appropriate primary antibodies (anti-OX-42, 1:500, Abcam
ab78457; anti-p-p38, 1:500, Cell Signaling). Membranes were
washed for 15 min in TBST between all incubations. Blots
were then incubated with a 1:1000 dilution of horseradish
peroxidase-conjugated secondary antibody (goat anti-rabbit
or -mouse, respectively) for 1.5 h at room temperature.
Respective bands were visualized by incubation with
enhanced chemiluminescence reagent (Boehringer Man-
nheim, Indianapolis, IN, USA) and exposure to X-ray ﬁlm,
which was developed and digitally analyzed using NIH Image
software, version 1.60.
5.7. TNF-α enzyme-linked immunosorbant assay
Rats from the different treatment groups were euthanized by
pentobarbital (4100 mg/kg i.p). Tissues derived from the L4/
L5 segment from the ipsilateral spinal cord dorsal horn of the
left side were removed, weighed, and immediately homo-
genized in solution containing 50 mM Tris, pH 7.4, 150 mM
NaCL, 1.5 mM MgCL2, 10% glycerol, 1% Trition X-100, 5 mm
EGTA, 0.5 ug/ml leupetin, 1 mM PMSF, 1 mM Na3VO4, 10 mM
NAF, and proteinase inhibitor cocktail. The TNF-levels (pg/mg
protein) were determined using the Chemikine TNF-α kit
following the protocol of the manufacturer.
5.8. Statistical analysis
The Western blots were quantiﬁed in two steps as follows.
First, β-tublin levels were used to normalize (e.g., determine
the ratio of OX-42 to β-tublin and p-38 amount) protein levels
and control for loading difference in the total protein amount.
Second. We presented changes of protein levels in treatment
groups as a percentage of those naive groups. All data are
presented as mean7SEM. Analysis of thermal hyperalgesia
experiments was performed using two-way repeated
measures-analysis of variance (RM-ANOVA). The expression
of OX-42, p–p38 and TNF-α was analyzed by two-way analysis
of variance (ANOVA) using SPSS 12.0 for Windows. The
standard for statistical signiﬁcance was po0.05.Conﬂict of interest statement
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